EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

Takashi Kumada iD, Hidenori Toyoda iD, Satoshi Yasuda iD, Yuichi Koshiyama iD, Takanori Ito iD, Tomoyuki Akita iD, Junko Tanaka iD

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Takashi Kumada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Faculty of Nursing, Gifu Kyoritsu University, Gifu, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic, RNA, Viral. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Roche Diagnostics Japan, Roche Diagnostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B (CHB) remain at risk of hepatocellular carcinoma (HCC). Novel covalently closed circular DNA activity biomarkers may improve risk stratification.

Aims

To comprehensively assess the association between serum HBV RNA and hepatitis B core‐related antigen (HBcrAg) levels, measured upon achieving undetectable HBV DNA levels, and subsequent HCC development in NA‐treated patients with CHB.

Methods

We retrospectively analysed 311 patients with CHB who achieved undetectable HBV DNA levels during NA therapy between 2000 and 2024. Serum HBV RNA (≥ 10 copies/mL) and HBcrAg (≥ 2.1 log U/mL) were measured in stored samples collected when HBV DNA first became undetectable. Cox regression analysis was performed to identify the factors associated with HCC development.

Results

During a median follow‐up of 11.0 years, 31 (10.0%) patients developed HCC. At viral suppression, 132 (42.4%) patients had HBV RNA ≥ 10 copies/mL. HCC incidence was significantly higher in patients with quantifiable HBV RNA than in those with unquantifiable HBV RNA (15‐year incidence, 17.8% vs. 8.8%, p = 0.026). Quantifiable HBV RNA independently predicted HCC (adjusted hazard ratio [aHR], 3.313; 95% confidence interval [CI]: 1.154–9.507; p = 0.026). HBcrAg showed no association (aHR, 0.821; 95% CI: 0.253–2.669; p = 0.743). Patients with quantifiable HBV RNA and albumin‐bilirubin score ≥ −2.60 had the highest risk (5‐year incidence: 15.8%).

Conclusions

HBV RNA levels at viral suppression predict HCC development in NA‐treated patients with CHB, outperforming HBcrAg. Incorporating HBV RNA assessment can improve risk‐stratified HCC surveillance strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatitis B, ChronicRNA, ViralHepatitis B virusAntiviral AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesAdultDNA, ViralAgedHepatitis B Core AntigensViral Load

Stichwörter der Autor:innen

Nucleos(t)ide analoguecovalently closed circular DNAhepatitis B core‐related antigenhepatitis B virus DNAhepatitis B virus RNAhepatocellular carcinoma

Substanzen

RNA, ViralAntiviral AgentsDNA, ViralHepatitis B Core Antigens

Autor:innen und Institutionen

  • Department of Nursing, Faculty of Nursing, Gifu Kyoritsu University, Gifu, Japan.
  • Department of Epidemiology, Infectious Disease Control, and Prevention, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan.
  • Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.
  • Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

ORCID-Profile: Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka

Förderung

  • Roche Diagnostics Japan
  • Roche Diagnostics

Zitieren

APA

Kumada, T., Toyoda, H., Yasuda, S., Koshiyama, Y., Ito, T., Akita, T., & Tanaka, J. (2025). Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70483

Vancouver

Kumada T, Toyoda H, Yasuda S, Koshiyama Y, Ito T, Akita T, et al. Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70483

BibTeX
@article{Kumada2025,
  author = {Kumada, Takashi and Toyoda, Hidenori and Yasuda, Satoshi and Koshiyama, Yuichi and Ito, Takanori and Akita, Tomoyuki and Tanaka, Junko},
  title = {Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70483}
}
Kostenlos starten →